GB9523752D0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB9523752D0
GB9523752D0 GBGB9523752.5A GB9523752A GB9523752D0 GB 9523752 D0 GB9523752 D0 GB 9523752D0 GB 9523752 A GB9523752 A GB 9523752A GB 9523752 D0 GB9523752 D0 GB 9523752D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9523752.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Pfizer Ltd Great Britain
Original Assignee
PFIZER Ltd
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9523752.5A priority Critical patent/GB9523752D0/en
Application filed by PFIZER Ltd, Pfizer Ltd Great Britain filed Critical PFIZER Ltd
Publication of GB9523752D0 publication Critical patent/GB9523752D0/en
Priority to PCT/EP1996/005020 priority patent/WO1997018814A1/en
Priority to TR1998/00902T priority patent/TR199800902T2/en
Priority to BR9611626A priority patent/BR9611626A/en
Priority to SK630-98A priority patent/SK63098A3/en
Priority to PL96326981A priority patent/PL326981A1/en
Priority to KR1019980703777A priority patent/KR19990071505A/en
Priority to AU75721/96A priority patent/AU709560B2/en
Priority to JP9519364A priority patent/JPH10513481A/en
Priority to CN96198486A priority patent/CN1215993A/en
Priority to CZ981554A priority patent/CZ155498A3/en
Priority to HU9903734A priority patent/HUP9903734A3/en
Priority to EP96938215A priority patent/EP0862437A1/en
Priority to NZ322053A priority patent/NZ322053A/en
Priority to CA002232715A priority patent/CA2232715A1/en
Priority to ZA9609722A priority patent/ZA969722B/en
Priority to TNTNSN96141A priority patent/TNSN96141A1/en
Priority to MA24397A priority patent/MA26410A1/en
Priority to ARP960105252A priority patent/AR004335A1/en
Priority to PE1996000831A priority patent/PE22898A1/en
Priority to YU62096A priority patent/YU62096A/en
Priority to HR9523752.5A priority patent/HRP960554A2/en
Priority to APAP/P/1996/000883A priority patent/AP718A/en
Priority to CO96061449A priority patent/CO4480020A1/en
Priority to IS4706A priority patent/IS4706A/en
Priority to BG102438A priority patent/BG102438A/en
Priority to OA9800058A priority patent/OA10687A/en
Priority to MX9804008A priority patent/MX9804008A/en
Priority to NO982302A priority patent/NO982302L/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB9523752.5A 1995-11-21 1995-11-21 Pharmaceutical formulations Pending GB9523752D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations
CA002232715A CA2232715A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
KR1019980703777A KR19990071505A (en) 1995-11-21 1996-11-11 Pharmaceutical preparations
JP9519364A JPH10513481A (en) 1995-11-21 1996-11-11 Pharmaceutical preparations
BR9611626A BR9611626A (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
SK630-98A SK63098A3 (en) 1995-11-21 1996-11-11 Controlled-release pharmaceutical formulation, process for its preparation and use of polyethyleneoxide
PL96326981A PL326981A1 (en) 1995-11-21 1996-11-11 Pharmaceutic preparations
PCT/EP1996/005020 WO1997018814A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
AU75721/96A AU709560B2 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
TR1998/00902T TR199800902T2 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations.
CN96198486A CN1215993A (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
CZ981554A CZ155498A3 (en) 1995-11-21 1996-11-11 Pharmaceutical preparation with controlled release, process of its preparation and use of polyethylene oxide
HU9903734A HUP9903734A3 (en) 1995-11-21 1996-11-11 Controlled-release pharmaceutical formulations for oral administration and method for preparing this
EP96938215A EP0862437A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations
NZ322053A NZ322053A (en) 1995-11-21 1996-11-11 Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers
ZA9609722A ZA969722B (en) 1995-11-21 1996-11-20 Pharmaceutical formulations.
YU62096A YU62096A (en) 1995-11-21 1996-11-20 Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof
TNTNSN96141A TNSN96141A1 (en) 1995-11-21 1996-11-20 PHARMACEUTICAL FORMULATIONS AND PROCESS FOR THEIR PRODUCTION
MA24397A MA26410A1 (en) 1995-11-21 1996-11-20 PHARMACEUTICAL FORMULATIONS AND PROCESS FOR THEIR PRODUCTION.
ARP960105252A AR004335A1 (en) 1995-11-21 1996-11-20 PHARMACEUTICAL FORMULATIONS
PE1996000831A PE22898A1 (en) 1995-11-21 1996-11-20 PHARMACEUTICAL FORMULATIONS
CO96061449A CO4480020A1 (en) 1995-11-21 1996-11-21 PHARMACEUTICAL FORMULATIONS
APAP/P/1996/000883A AP718A (en) 1995-11-21 1996-11-21 A controlled-release pharmaceutical formulation for oral administration.
HR9523752.5A HRP960554A2 (en) 1995-11-21 1996-11-21 Pharmaceutical formulations
IS4706A IS4706A (en) 1995-11-21 1998-03-31 pharmaceutical compositions
BG102438A BG102438A (en) 1995-11-21 1998-05-08 Medicamentous form
OA9800058A OA10687A (en) 1995-11-21 1998-05-19 Pharmaceutical formulations
MX9804008A MX9804008A (en) 1995-11-21 1998-05-20 Pharmaceutical formulations.
NO982302A NO982302L (en) 1995-11-21 1998-05-20 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
GB9523752D0 true GB9523752D0 (en) 1996-01-24

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9523752.5A Pending GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Country Status (29)

Country Link
EP (1) EP0862437A1 (en)
JP (1) JPH10513481A (en)
KR (1) KR19990071505A (en)
CN (1) CN1215993A (en)
AP (1) AP718A (en)
AR (1) AR004335A1 (en)
AU (1) AU709560B2 (en)
BG (1) BG102438A (en)
BR (1) BR9611626A (en)
CA (1) CA2232715A1 (en)
CO (1) CO4480020A1 (en)
CZ (1) CZ155498A3 (en)
GB (1) GB9523752D0 (en)
HR (1) HRP960554A2 (en)
HU (1) HUP9903734A3 (en)
IS (1) IS4706A (en)
MA (1) MA26410A1 (en)
MX (1) MX9804008A (en)
NO (1) NO982302L (en)
NZ (1) NZ322053A (en)
OA (1) OA10687A (en)
PE (1) PE22898A1 (en)
PL (1) PL326981A1 (en)
SK (1) SK63098A3 (en)
TN (1) TNSN96141A1 (en)
TR (1) TR199800902T2 (en)
WO (1) WO1997018814A1 (en)
YU (1) YU62096A (en)
ZA (1) ZA969722B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
CZ20002199A3 (en) * 1997-12-16 2001-10-17 Pfizer Products Inc. Combination, composition and kits for treating impotence and female sexual dysfunction
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
WO2005107702A2 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) * 2004-05-28 2006-04-27 한미약품 주식회사 Sustained release composition for oral administration of niacin
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) * 2004-11-20 2007-02-07 대우약품공업주식회사 Sustained-release tablets containing doxazosin
US20090214645A1 (en) * 2005-08-22 2009-08-27 Andrea Kramer Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ATE496623T1 (en) 2006-04-26 2011-02-15 Supernus Pharmaceuticals Inc OXCARBAZEPINE CONTROLLED RELEASE PREPARATIONS WITH SIGMOIDAL RELEASE PROFILE
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN107235980A (en) 2006-05-04 2017-10-10 勃林格殷格翰国际有限公司 Polymorph
CN100396282C (en) * 2006-07-25 2008-06-25 山东省医药工业研究所 Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
MX2010009990A (en) 2008-03-11 2010-12-15 Depomed Inc Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations
MA33046B1 (en) 2009-02-13 2012-02-01 Boehringer Ingelheim Int Pharmaceutical composition containing sglt-2 inhibitor and dpp-iv inhibitor and optionally another agent against diabetes and its use
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
AU2010239311B2 (en) 2009-04-20 2014-05-22 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
KR101927068B1 (en) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
BR112013000626B1 (en) 2010-07-09 2019-11-26 Bhv Pharma Inc pharmaceutical formulation and method for preparing a dosage form thereof
CA2815024A1 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112013017411B1 (en) 2011-01-07 2022-03-22 Anji Pharma (Us) Llc Use of a composition comprising metformin or a salt thereof
CN102058555A (en) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 Doxazosin controlled release tablet
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN102188431A (en) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 Doxazosin mesylate sustained-release tablets and preparation method thereof
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
ES2929025T3 (en) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptin, a xanthine derivative as a dpp-4 inhibitor, for use in the treatment of SIRS and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN105616378A (en) * 2014-10-31 2016-06-01 康普药业股份有限公司 Fluconazole capsule and preparation method therefor
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 Combination of linagliptin and metformin
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (en) * 1982-07-06 1988-12-21 Lepetit Spa A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
DE69104045T2 (en) * 1990-07-23 1995-02-02 Alza Corp OSMOTIC DEVICE FOR DELIVERING NICOTIN TO BE ORALED.

Also Published As

Publication number Publication date
NZ322053A (en) 1999-11-29
JPH10513481A (en) 1998-12-22
TR199800902T2 (en) 1998-09-21
CO4480020A1 (en) 1997-07-09
NO982302L (en) 1998-07-17
AR004335A1 (en) 1998-11-04
HUP9903734A3 (en) 2000-04-28
AP718A (en) 1999-01-06
HRP960554A2 (en) 1998-02-28
CZ155498A3 (en) 1999-03-17
YU62096A (en) 1999-03-04
IS4706A (en) 1998-03-31
BG102438A (en) 1999-01-29
MX9804008A (en) 1998-09-30
ZA969722B (en) 1998-05-20
AP9600883A0 (en) 1997-01-31
KR19990071505A (en) 1999-09-27
WO1997018814A1 (en) 1997-05-29
TNSN96141A1 (en) 2005-03-15
PL326981A1 (en) 1998-11-09
CN1215993A (en) 1999-05-05
BR9611626A (en) 1999-06-01
HUP9903734A2 (en) 2000-03-28
NO982302D0 (en) 1998-05-20
PE22898A1 (en) 1998-05-07
AU7572196A (en) 1997-06-11
SK63098A3 (en) 1999-05-07
OA10687A (en) 2002-11-27
MA26410A1 (en) 2004-12-20
EP0862437A1 (en) 1998-09-09
CA2232715A1 (en) 1997-05-29
AU709560B2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
EG23826A (en) Pharmaceutical formulations
AP9600883A0 (en) Pharmaceutical formulations
GB9408117D0 (en) Pharmaceutical formulations
GB9519363D0 (en) Pharmaceutical formulation
ZA951781B (en) Pharmaceutical formulations
EP0862431A4 (en) Pharmaceutical formulation
ZA967827B (en) Pharmaceutical compositions
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
GB9523566D0 (en) Pharmaceutical formulation
ZA96526B (en) Novel pharmaceutical formulation
AP9801196A0 (en) Pharmaceutical preparation
ZA96392B (en) Pharmaceutical formulations
GB9413542D0 (en) Pharmaceutical formulations
GB9500978D0 (en) Pharmaceutical formulations
ZA967542B (en) Pharmaceutical combination preparation comprising keto-profen
GB9516584D0 (en) Pharmaceutical formulations
GB9508989D0 (en) Pharmaceutical formulations
GB9503752D0 (en) Pharmaceutical formulations
HUP9602732A2 (en) Pharmaceutical composition comprising lanperisone
ZA953239B (en) Pharmaceutical formulations
GB9408161D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations
GB9417953D0 (en) Pharmaceutical formulations